SEC Form 4 · accession 0001209191-17-043849
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 9:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2017 | J | 1,000 | $18.3175 | A | 178,519 | D | |
| Common StockF2 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by Mr. Browne under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on June 30, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Browne purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended June 30, 2017.
- F2These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.